SCHEMBL4179743

SCHEMBL4179743

CCCn1c(=O)c2c(nc(Cc3ccccc3)n2CCNCC)n(CCc2ccccc2NC(=O)CCC(=O)O)c1=O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.43
ADORA2B P29275 6/20 0.42
ADORA2A P29274 3/20 0.42
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
ADORA1 P30542 3/20 0.38
ADORA3 P0DMS8 2/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4183596 0.91 TSHR (0.40) TSHRADORA2BADORA2ATP53SMN1; SMN2
SCHEMBL4312584 0.90 TSHR (0.42) TSHRADORA2BADORA2ATP53SMN1; SMN2
SCHEMBL4171985 0.89 ADORA2B (0.43) TSHRADORA2BADORA2ATP53SMN1; SMN2
SCHEMBL5835532 0.88 MAPT (0.42) TSHRADORA2BADORA2ATP53SMN1; SMN2
SCHEMBL4183604 0.86 ADORA1 (0.43) TSHRADORA2BADORA2ATP53SMN1; SMN2
SCHEMBL4174089 0.84 CHRNB2 (0.38) TSHRADORA2BADORA2ATP53THRB
SCHEMBL5831724 0.84 TSHR (0.37) TSHRADORA2BADORA2ATP53MEN1
SCHEMBL4184656 0.84 CHRNB2 (0.38) TSHRADORA2BADORA2AADORA1L3MBTL1
SCHEMBL4171247 0.83 ADORA2B (0.47) TSHRADORA2BADORA2ASMN1; SMN2ADORA1
SCHEMBL4178538 0.82 TSHR (0.36) TSHRADORA2BADORA2AADORA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090068101-A9 A1 Adenosine Receptor Antagonists ENDACEA, INC. (US) 2009-03-12 US disclosed
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility ENDACEA, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility HRH3, HRH1, HRH2 TSHR 1275/4885ADORA2B 9/4885ADORA2A 7/4885
US-20090068101-A9 A1 Adenosine Receptor Antagonists ADORA1, ADORA3, ADORA2A TSHR 197/4885ADORA2B 4/4885ADORA2A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.